Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Mining the adenovirus virome for oncolytics against multiple solid tumor types.

Chen CY, Weaver EA, Khare R, May SM, Barry MA.

Cancer Gene Ther. 2011 Oct;18(10):744-50. doi: 10.1038/cgt.2011.47. Epub 2011 Sep 2.

2.

Species D adenoviruses as oncolytics against B-cell cancers.

Chen CY, Senac JS, Weaver EA, May SM, Jelinek DF, Greipp P, Witzig T, Barry MA.

Clin Cancer Res. 2011 Nov 1;17(21):6712-22. doi: 10.1158/1078-0432.CCR-11-0968. Epub 2011 Sep 2.

3.

Infection and killing of multiple myeloma by adenoviruses.

Senac JS, Doronin K, Russell SJ, Jelinek DF, Greipp PR, Barry MA.

Hum Gene Ther. 2010 Feb;21(2):179-90. doi: 10.1089/hum.2009.082.

4.

Mining the adenovirus "virome" for systemic oncolytics.

Barry MA, Weaver EA, Chen CY.

Curr Pharm Biotechnol. 2012 Jul;13(9):1804-8. Review.

PMID:
21740366
5.

Characterization of human adenovirus serotypes 5, 6, 11, and 35 as anticancer agents.

Shashkova EV, May SM, Barry MA.

Virology. 2009 Nov 25;394(2):311-20. doi: 10.1016/j.virol.2009.08.038. Epub 2009 Sep 18.

6.

Virotherapy using a novel chimeric oncolytic adenovirus prolongs survival in a human pancreatic cancer xenograft model.

Chu QD, Sun G, Pope M, Luraguiz N, Curiel DT, Kim R, Li BD, Mathis JM.

Surgery. 2012 Sep;152(3):441-8. doi: 10.1016/j.surg.2012.05.040. Epub 2012 Jul 31.

7.

Modification of the early gene enhancer-promoter improves the oncolytic potency of adenovirus 11.

Wong HH, Jiang G, Gangeswaran R, Wang P, Wang J, Yuan M, Wang H, Bhakta V, Müller H, Lemoine NR, Wang Y.

Mol Ther. 2012 Feb;20(2):306-16. doi: 10.1038/mt.2011.242. Epub 2011 Nov 15.

8.

Systemic delivery of a novel liver-detargeted oncolytic adenovirus causes reduced liver toxicity but maintains the antitumor response in a breast cancer bone metastasis model.

Zhang Z, Krimmel J, Zhang Z, Hu Z, Seth P.

Hum Gene Ther. 2011 Sep;22(9):1137-42. doi: 10.1089/hum.2011.003. Epub 2011 Jun 8.

9.

Comparison of adenoviruses as oncolytics and cancer vaccines in an immunocompetent B cell lymphoma model.

Weaver EA, Chen CY, May SM, Barry ME, Barry MA.

Hum Gene Ther. 2011 Sep;22(9):1095-100. doi: 10.1089/hum.2011.071. Epub 2011 Sep 6.

10.

ORCA-010, a novel potency-enhanced oncolytic adenovirus, exerts strong antitumor activity in preclinical models.

Dong W, van Ginkel JW, Au KY, Alemany R, Meulenberg JJ, van Beusechem VW.

Hum Gene Ther. 2014 Oct;25(10):897-904. doi: 10.1089/hum.2013.229. Epub 2014 Sep 17.

11.

A novel immunocompetent murine model for replicating oncolytic adenoviral therapy.

Zhang L, Hedjran F, Larson C, Perez GL, Reid T.

Cancer Gene Ther. 2015 Jan;22(1):17-22. doi: 10.1038/cgt.2014.64. Epub 2014 Dec 19.

12.

Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus.

Diaconu I, Cerullo V, Hirvinen ML, Escutenaire S, Ugolini M, Pesonen SK, Bramante S, Parviainen S, Kanerva A, Loskog AS, Eliopoulos AG, Pesonen S, Hemminki A.

Cancer Res. 2012 May 1;72(9):2327-38. doi: 10.1158/0008-5472.CAN-11-2975. Epub 2012 Mar 6.

13.

Enhanced antitumor efficacy of fiber-modified, midkine promoter-regulated oncolytic adenovirus in human malignant mesothelioma.

Takagi-Kimura M, Yamano T, Tamamoto A, Okamura N, Okamura H, Hashimoto-Tamaoki T, Tagawa M, Kasahara N, Kubo S.

Cancer Sci. 2013 Nov;104(11):1433-9. doi: 10.1111/cas.12267. Epub 2013 Sep 23.

14.

An oncolytic adenovirus defective in pRb-binding (dl922-947) can efficiently eliminate pancreatic cancer cells and tumors in vivo in combination with 5-FU or gemcitabine.

Bhattacharyya M, Francis J, Eddouadi A, Lemoine NR, Halldén G.

Cancer Gene Ther. 2011 Oct;18(10):734-43. doi: 10.1038/cgt.2011.45. Epub 2011 Aug 12.

PMID:
21836633
15.

pH-sensitive oncolytic adenovirus hybrid targeting acidic tumor microenvironment and angiogenesis.

Choi JW, Jung SJ, Kasala D, Hwang JK, Hu J, Bae YH, Yun CO.

J Control Release. 2015 May 10;205:134-43. doi: 10.1016/j.jconrel.2015.01.005. Epub 2015 Jan 7.

16.

Oncolytic adenovirus characterization: activity and immune responses.

Gil-Hoyos R, Miguel-Camacho J, Alemany R.

Methods Mol Biol. 2014;1089:117-32. doi: 10.1007/978-1-62703-679-5_9.

PMID:
24132482
17.

Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer.

Hemminki O, Diaconu I, Cerullo V, Pesonen SK, Kanerva A, Joensuu T, Kairemo K, Laasonen L, Partanen K, Kangasniemi L, Lieber A, Pesonen S, Hemminki A.

Mol Ther. 2012 Sep;20(9):1821-30. doi: 10.1038/mt.2012.115. Epub 2012 Aug 7.

18.

Oncolytic adenovirus and doxorubicin-based chemotherapy results in synergistic antitumor activity against soft-tissue sarcoma.

Siurala M, Bramante S, Vassilev L, Hirvinen M, Parviainen S, Tähtinen S, Guse K, Cerullo V, Kanerva A, Kipar A, Vähä-Koskela M, Hemminki A.

Int J Cancer. 2015 Feb 15;136(4):945-54. doi: 10.1002/ijc.29048. Epub 2014 Jul 3.

19.

MicroRNA regulation of oncolytic adenovirus 6 for selective treatment of castration-resistant prostate cancer.

Zhang Z, Zhang X, Newman K, Liu X, Seth P.

Mol Cancer Ther. 2012 Nov;11(11):2410-8. doi: 10.1158/1535-7163.MCT-12-0157. Epub 2012 Aug 22. Erratum in: Mol Cancer Ther. 2014 Jan;13(1):271. Seth, Prem [added].

20.

Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4.

Dias JD, Hemminki O, Diaconu I, Hirvinen M, Bonetti A, Guse K, Escutenaire S, Kanerva A, Pesonen S, Löskog A, Cerullo V, Hemminki A.

Gene Ther. 2012 Oct;19(10):988-98. doi: 10.1038/gt.2011.176. Epub 2011 Nov 10.

PMID:
22071969

Supplemental Content

Support Center